{"slug":"merck-co","name":"머크 (미국 MSD)","name_en":"Merck & Co.","ticker":"MRK","updated_at":"2026-07-12T04:47:12.948+00:00","canonical":"https://valuechain.wiki/merck-co","citable":"밸류체인 그래프 기준 머크 (미국 MSD)의 직접 연결 기업은 3곳(관계 기준 공급 3·매출 0)이고, 사슬을 2차까지 넓히면 3곳에 닿는다. 링크의 근거 출처는 4건이며 그중 1차공시가 2건이다 (valuechain.wiki, 2026-07-12 기준).","citable_en":"Per the valuechain.wiki graph, Merck & Co. is directly linked to 3 companies (3 supply, 0 revenue relationships) and reaches 3 companies within two hops; the links are backed by 4 dated sources, 2 of them primary filings (as of 2026-07-12).","kicker":"S&P 500 · 제약 · 키트루다(면역항암)","kicker_en":"S&P 500 · pharma · Keytruda (immuno-oncology)","lead":"머크(미국 MSD)는 세계 최다 매출 의약품 면역항암제 키트루다를 보유한 미국 대형 제약사다(독일 머크KGaA와 별개 회사). 키트루다는 2025년 매출 $316.8억(+7%)으로 회사 실적을 좌우하는데, 2028년 미국 특허 만료(패턴트 클리프)가 최대 리스크다. 이에 대응해 알테오젠의 ALT-B4 원천기술을 독점 라이선스해 피하주사(SC) 제형으로 전환, 특허 수명을 늘리려 한다. 백신(가다실)·동물약품이 보조 축이다.","lead_en":"Merck & Co. (MSD outside the US) is a US pharma major behind Keytruda, the world's best-selling drug (distinct from Germany's Merck KGaA). Keytruda, at $31.68B in 2025 (+7%), dominates results, and its 2028 US patent cliff is the central risk. To counter it, Merck exclusively licenses Alteogen's ALT-B4 platform to convert Keytruda into a subcutaneous (SC) formulation and extend patent life. Vaccines (Gardasil) and animal health are supporting axes.","segments":{"fy":2025,"parts":[{"desc":"키트루다 $316.8억(+7%, 전사 매출의 49%) — 세계 1위 의약품이자 회사 실적의 핵심. 2028년 미국 물질특허 만료가 최대 리스크로, SC 제형(알테오젠 ALT-B4)·병용·용법 특허로 수명을 늘리려 한다.","name":"항암 (키트루다)"},{"desc":"가다실 $52.3억(전년 $85.8억서 급감)·윈리베어 $14.4억·린파자(AZ) $14.5억·렌비마(에자이) $10.5억 — 키트루다 편중을 더는 다각화 축.","name":"백신·비항암 (가다실·윈리베어·얼라이언스)"},{"desc":"매출 $63.5억(+8%, 가축 $39.0억·반려 $24.6억) — 인체 항암 사이클과 상관 낮은 안정 축(브라벡토 $11억).","name":"동물약품 (애니멀헬스)"}],"total":"총매출 $650.1억 (2025, +1.3%)·키트루다 49%·순현금 M&A로 파이프라인 매입","source":"Merck 10-K FY2025","concentration":"키트루다 49% 편중·2028 특허절벽. 알테오젠(SC)·다이이치(ADC)·모더나(암백신)·베로나 인수로 대응."},"segments_en":{"parts":[{"desc":"The immuno-oncology drug Keytruda — the world's top seller at $31.68B in 2025 (+7%), the core of results; the 2028 patent cliff is the risk.","name":"Oncology (Keytruda)"},{"desc":"The HPV vaccine Gardasil — a diversification axis reducing oncology concentration.","name":"Vaccines (Gardasil)"},{"desc":"Animal-health products — a stable axis with low correlation to human pharma.","name":"Animal health"}]},"returns_yearly":{"2021":1.8,"2022":49.4,"2023":1,"2024":-6.3,"2025":9.8,"2026":19.1},"return_asof":"2026-07-10","value_chain":{"leading":[],"benefiting":[{"slug":"moderna","name":"모더나","name_en":"Moderna","tier":1,"returns_yearly":{"2021":143.1,"2022":-29.3,"2023":-44.6,"2024":-58.2,"2025":-29.1,"2026":131.5}},{"slug":"daiichi-sankyo","name":"다이이치산쿄","name_en":"Daiichi Sankyo","tier":1,"returns_yearly":{"2021":-23.1,"2022":59.8,"2023":9.7,"2024":-2.1,"2025":-32.4,"2026":-2.4}},{"slug":"alteogen","name":"알테오젠","name_en":"ALTEOGEN","tier":2,"returns_yearly":{"2021":-45.9,"2022":-8.2,"2023":110.6,"2024":380.6,"2025":11.3,"2026":-21.5}}],"analysis":"머크의 논지는 세계 최대 약물 키트루다의 지배력과 2028년 특허 만료를 둘러싼 방어전이다. 키트루다는 2025년 매출 $316.8억(+7%)으로 세계 1위 의약품이자 회사 실적의 핵심이지만, 2028년 미국 특허 만료가 바이오시밀러 잠식 리스크를 예고한다. 방어 전략의 축은 알테오젠 ALT-B4를 독점 라이선스한 피하주사(SC) 제형 전환으로, 투여 편의성과 새 특허로 프랜차이즈 수명을 늘리려는 것이다 — 머크는 알테오젠에 계약금·마일스톤(2025년 FDA $25M·EU $15M)과 순매출 2% 로열티를 지급한다. 백신(가다실)·동물약품이 매출 다각화 축이다. 재평가 트리거는 키트루다 SC 전환 성공·침투율, 특허 만료 대비 파이프라인, 그리고 신규 항암·백신 승인이다.","analysis_en":"Merck's thesis is the dominance of Keytruda, the world's largest drug, and the defensive fight around its 2028 patent cliff. Keytruda, at $31.68B in 2025 (+7%), is the world's top-selling medicine and the core of results, but its 2028 US patent expiry foreshadows biosimilar erosion. The centerpiece of the defense is converting it to a subcutaneous (SC) formulation via an exclusive license to Alteogen's ALT-B4, aiming to extend the franchise through dosing convenience and new patents — Merck pays Alteogen upfronts, milestones ($25M FDA and $15M EU in 2025) and a 2% net-sales royalty. Vaccines (Gardasil) and animal health diversify revenue. Re-rating triggers are the success and uptake of Keytruda SC, the pipeline ahead of the patent cliff, and new oncology and vaccine approvals.","analysis_asof":"2026-07-10"},"edges":[{"direction":"revenue","counterparty":"종양내과 시장 (키트루다)","counterparty_slug":null,"confidence":"high","metric":{"type":"amount","unit":"USD","as_of":"2025-12","basis":"10-K","value":31680000000,"period":"2025 키트루다 매출","basis_en":"10-K","share_of_total_pct":49},"note":"키트루다가 세계 최다 매출 의약품 — 2025년 $316.8억(+7%). 2028년 미국 특허 만료를 앞두고 피하주사 제형 전환 진행.","note_en":"Keytruda is the world's best-selling drug at $31.68B in 2025 (+7%); subcutaneous switch underway ahead of the 2028 US patent cliff.","sources":[{"stance":"confirms","publisher":"Merck & Co. (SEC EDGAR)","publisher_en":"Merck & Co. (SEC EDGAR)","kind":"filing","lang":"en","published_at":"2026-02-24","url":"https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm","title":"머크(MSD) 10-K (FY2025)","title_en":"Merck & Co. Form 10-K (FY2025)","excerpt":"In 2025, sales of Keytruda represented 49% of the Company's total sales ($31,680M); US composition-of-matter patent expires 2028.","excerpt_en":"In 2025, sales of Keytruda represented 49% of the Company's total sales ($31,680M); US composition-of-matter patent expires 2028."},{"stance":"mentions","publisher":"Wells Fargo·BofA (via Investing.com)","publisher_en":"Wells Fargo·BofA (via Investing.com)","kind":"research","lang":"en","published_at":"2026-01-15","url":"https://www.investing.com/news/analyst-ratings/bmo-capital-raises-merck-stock-price-target-on-potential-keytruda-patent-extension-93CH-4484365","title":"머크 목표가 상향 — Wells Fargo OW $135·BofA Buy $132·컨센 $118","title_en":"Merck target raised — Wells Fargo OW $135, BofA Buy $132, consensus ~$118","excerpt":"Analyst consensus ~$118 (Wells Fargo Overweight $135, BofA Buy $132); thesis hinges on the post-Keytruda diversification engine and 2028 cliff mitigation.","excerpt_en":"Analyst consensus ~$118 (Wells Fargo Overweight $135, BofA Buy $132); thesis hinges on the post-Keytruda diversification engine and 2028 cliff mitigation."}]},{"direction":"investment","counterparty":"베로나 파마 인수 (COPD·Ohtuvayre, 2025)","counterparty_slug":null,"confidence":"high","metric":{"type":"amount","unit":"USD","as_of":"2025-10","basis":"Verona Pharma 인수 현금대가","value":10400000000,"period":"2025","basis_en":"Verona Pharma acquisition cash consideration"},"note":"2025년 10월 호흡기 바이오텍 베로나 파마를 현금 $104억에 인수해 COPD 치료제 Ohtuvayre(엔시펜트린)를 확보 — 키트루다 이후를 대비한 M&A 다각화의 2025년 대표 딜이다. 머크는 이 외에도 EyeBio·하푸운·프로메테우스 등 볼트온 인수와 다이이치·모더나 라이선스로 파이프라인을 사서 특허절벽을 메운다.","note_en":"In October 2025 Merck acquired respiratory biotech Verona Pharma for $10.4B in cash, gaining the COPD drug Ohtuvayre (ensifentrine) — the flagship 2025 M&A of its post-Keytruda diversification. Beyond this, Merck fills the cliff by buying pipeline via bolt-ons (EyeBio, Harpoon, Prometheus) and licenses (Daiichi, Moderna).","sources":[{"stance":"confirms","publisher":"Merck & Co. (SEC EDGAR)","publisher_en":"Merck & Co. (SEC EDGAR)","kind":"filing","lang":"en","published_at":"2026-02-24","url":"https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm","title":"머크(MSD) 10-K (FY2025)","title_en":"Merck & Co. Form 10-K (FY2025)","excerpt":"The Company used net proceeds to fund a portion of the $10.4 billion cash consideration for the October 2025 acquisition of Verona Pharma; cash flow: Acquisition of Verona Pharma, net of cash acquired ($10,042M).","excerpt_en":"The Company used net proceeds to fund a portion of the $10.4 billion cash consideration for the October 2025 acquisition of Verona Pharma; cash flow: Acquisition of Verona Pharma, net of cash acquired ($10,042M)."}]},{"direction":"revenue","counterparty":"백신·동물약·비항암 (가다실·애니멀헬스·윈리베어 등)","counterparty_slug":null,"confidence":"high","metric":{"type":"amount","unit":"USD","as_of":"2025-12","basis":"Animal Health 2025 매출(비항암 다각화)","value":6354000000,"period":"2025","basis_en":"Animal Health 2025 sales (non-oncology diversification)"},"note":"키트루다 편중(전사 매출의 49%)을 더는 다각화 축이자 2028 특허절벽의 완충 — 동물약품 $63.5억(+8%), 가다실 $52.3억(전년 $85.8억서 급감), 윈리베어 $14.4억, 얼라이언스 매출 린파자 $14.5억·렌비마 $10.5억. 백신·동물약은 인체 항암 사이클과 상관이 낮아 실적 변동성을 낮춘다.","note_en":"The axis diversifying away from Keytruda concentration (49% of total) and a buffer to the 2028 patent cliff — Animal Health $6.35B (+8%), Gardasil $5.23B (down from $8.58B), Winrevair $1.44B, alliance revenue Lynparza $1.45B and Lenvima $1.05B. Vaccines and animal health have low correlation to the human-oncology cycle, lowering earnings volatility.","sources":[{"stance":"confirms","publisher":"Merck & Co. (SEC EDGAR)","publisher_en":"Merck & Co. (SEC EDGAR)","kind":"filing","lang":"en","published_at":"2026-02-24","url":"https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm","title":"머크(MSD) 10-K (FY2025)","title_en":"Merck & Co. Form 10-K (FY2025)","excerpt":"2025 sales: Gardasil/Gardasil 9 $5,233M, Winrevair $1,443M, Animal Health $6,354M (Livestock $3,896M, Companion $2,458M); alliance revenue Lynparza $1,450M, Lenvima $1,053M.","excerpt_en":"2025 sales: Gardasil/Gardasil 9 $5,233M, Winrevair $1,443M, Animal Health $6,354M (Livestock $3,896M, Companion $2,458M); alliance revenue Lynparza $1,450M, Lenvima $1,053M."}]},{"direction":"cost","counterparty":"알테오젠","counterparty_slug":"alteogen","confidence":"high","metric":{"type":"amount","unit":"USD","as_of":"2025-12-01","basis":"DART 사업보고서·마일스톤 공시","value":4317000000,"period":"최대 총 계약금액(로열티 별도)","basis_en":"DART filings"},"note":"키트루다SC(피하주사 펨브롤리주맙)의 제형 변환에 알테오젠 ALT-B4 원천기술을 독점 라이선스. 알테오젠에 계약금·마일스톤(2025년 FDA $25M·EU $15M)과 순매출 2% 로열티 지급.","note_en":"Licenses Alteogen's ALT-B4 exclusively to convert Keytruda into subcutaneous pembrolizumab (Keytruda SC); pays Alteogen upfronts, milestones (US$25M FDA and US$15M EU in 2025) and a 2% net-sales royalty.","sources":[{"stance":"confirms","publisher":"BigGo Finance","publisher_en":"BigGo Finance","kind":"news","lang":"en","published_at":"2026-01-22","url":"https://finance.biggo.com/news/nXU945sBXdIeighIpkwS","title":"Alteogen Merck royalty rate confirmed at 2%; Hana cuts target to 580,000 won","title_en":"Alteogen Merck royalty rate confirmed at 2%; Hana Securities cuts target price","excerpt":"머크가 알테오젠에 지급할 키트루다SC 로열티율 2%로 확인.","excerpt_en":"Merck's Keytruda SC royalty to Alteogen confirmed at 2%."},{"stance":"confirms","publisher":"금융감독원 전자공시(DART)","publisher_en":"DART (FSS)","kind":"filing","lang":"ko","published_at":"2025-10-01","url":"https://opendart.fss.or.kr/api/document.xml?rcept_no=20251001900011","title":"투자판단 관련 주요경영사항 (ALT-B4 마일스톤 기술료 수령, US$25M)","title_en":"Material disclosure: ALT-B4 milestone US$25M (Keytruda SC FDA approval)","excerpt":"MSD, ALT-B4 마일스톤 US$25M 지급(키트루다SC 미국 FDA 허가).","excerpt_en":"MSD pays US$25M ALT-B4 milestone on Keytruda SC US FDA approval."}]},{"direction":"cost","counterparty":"다이이치산쿄 (ADC 공동개발)","counterparty_slug":"daiichi-sankyo","confidence":"high","metric":{"qualifier":"three_ADC_codevelopment"},"note":"키트루다 이후를 겨냥한 항체약물접합체(ADC) 3종을 다이이치산쿄와 공동개발 — 파트리투맙 데룩스테칸(MK-1022)·이피나타맙 데룩스테칸(MK-2400)·랄루도타툭 데룩스테칸(MK-5909). 머크가 선급·마일스톤을 대고 개발·상업화를 분담하는 구조로, 2028 특허절벽을 메울 파이프라인의 핵심 상류 의존이다.","note_en":"Co-develops three antibody-drug conjugates (ADCs) with Daiichi Sankyo aimed at the post-Keytruda era — patritumab deruxtecan (MK-1022), ifinatamab deruxtecan (MK-2400) and raludotatug deruxtecan (MK-5909). Merck funds upfronts/milestones and shares development and commercialization, a key upstream dependence for the pipeline meant to fill the 2028 cliff.","sources":[{"stance":"confirms","publisher":"Merck & Co. (SEC EDGAR)","publisher_en":"Merck & Co. (SEC EDGAR)","kind":"filing","lang":"en","published_at":"2026-02-24","url":"https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm","title":"머크(MSD) 10-K (FY2025)","title_en":"Merck & Co. Form 10-K (FY2025)","excerpt":"Patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan are being developed as part of a collaboration with Daiichi Sankyo.","excerpt_en":"Patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan are being developed as part of a collaboration with Daiichi Sankyo."}]},{"direction":"cost","counterparty":"모더나 (V940 개인맞춤 암백신 공동개발)","counterparty_slug":"moderna","confidence":"high","metric":{"qualifier":"V940_codevelopment"},"note":"모더나와 개인맞춤 신항원 암백신 V940(intismeran autogene, mRNA-4157)을 공동개발 — 키트루다와 병용해 흑색종·비소세포폐암 보조요법에서 3상 진행. 머크가 옵션을 행사해 개발비·손익을 분담하는 구조로, mRNA 플랫폼을 키트루다 프랜차이즈 방어에 붙인 파이프라인 베팅이다.","note_en":"Co-develops the individualized neoantigen cancer vaccine V940 (intismeran autogene, mRNA-4157) with Moderna — in Phase 3 as adjuvant therapy with Keytruda for melanoma and NSCLC. Merck exercised its option and shares development costs and economics, a pipeline bet attaching an mRNA platform to the defense of the Keytruda franchise.","sources":[{"stance":"confirms","publisher":"Merck & Co. (SEC EDGAR)","publisher_en":"Merck & Co. (SEC EDGAR)","kind":"filing","lang":"en","published_at":"2026-02-24","url":"https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm","title":"머크(MSD) 10-K (FY2025)","title_en":"Merck & Co. Form 10-K (FY2025)","excerpt":"V940 (mRNA-4157), intismeran autogene, is being developed as part of a collaboration with Moderna, Inc., evaluated in combination with Keytruda.","excerpt_en":"V940 (mRNA-4157), intismeran autogene, is being developed as part of a collaboration with Moderna, Inc., evaluated in combination with Keytruda."}]}]}